MPM BioImpact

Investing
in the Future
of Medicine

We create and invest in biotech companies with innovative technologies that are developing life-saving drugs for patients. We invest in both private and public companies, providing a unique longitudinal view of drug development across the industry.

LEARN MORE

30+ Years of Biotech Investing

58 FDA-approved drugs

39 Companies founded since 2010*

^*Companies created by MPM BioImpact include portfolio companies where MPM BioImpact was a co-founder or early lead investor from 2010 to today, representing the period that MPM BioImpact’s strategy has been focused on company creation.

We are Company Creators

We built Orna Therapeutics to create a new class of coding RNA medicines that outperforms mRNA.

Orna’s circular RNA technology (oRNA) and best-in-class non-viral delivery are fundamentally changing the landscape of treatment modalities,^* starting with replacing cell therapies and improving vaccines.

VISIT THE ORNA SITE

We built Aktis Oncology to realize the transformative potential of alpha radio-pharmaceuticals for patients with solid tumors.

Aktis is pioneering miniprotein actinium-conjugates to deliver breakthrough efficacy and enhanced safety compared to earlier generations of radiopharmaceuticals, while treating a broader set of cancer patients beyond prostate and neuroendocrine tumors.

VISIT THE Aktis SITE

Scientific illustration depicting Aktis’ selective tumor-targeting radiopharmaceuticals penetrating tumors.

We built ElevateBio to power transformative cell, gene, and RNA therapies.

ElevateBio combines manufacturing, next-generation technologies, and therapeutic development all under one roof.

VISIT THE ELEVATEBIO SITE

Diagram depicting ElevateBio’s integrated ecosystem of technologies and capabilities to develop a spectrum of cell and gene therapies and regenerative medicines.

We built NextPoint Therapeutics to target a fundamentally new axis in cancer biology.

NextPoint is translating a breakthrough in cancer research into first-in-class, precision therapies for patients in need.

VISIT THE NEXTPOINT SITE

3D scientific visual depicting NextPoint’s approach to utilizing the upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

“MPM BioImpact’s commitment to creating transformative medicines for patients has been evident since Orna’s inception. MPM BioImpact saw the potential for circular RNA to solve key challenges with existing cell therapies, and it is their vision that drew me to be part of this exciting effort.”^**

Tom Barnes, Ph.D.

Board Member & SCIENTIFIC ADVISORY BOARD Chair

Amit Munshi

CEO

Daniel Anderson, Ph.D.

Co-Founder & Professor, MIT

In the News

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

*Garber, K., "Orna Therapeutics: circular logic," Nature Biotechnology, 05 August 2022, https://doi.org/10.1038/d41587-022-00005-1

^**Tom Barnes is not receiving direct compensation for this quote, but has a pecuniary interest that arises from the relationship. Tom receives compensation from certain MPM BioImpact funds.

“Aktis was founded at MPM BioImpact with an ambitious vision to transform the radiopharmaceutical field. The team at MPM BioImpact has lent significant leadership, expertise, and support to enable Aktis to realize this significant patient impact potential.”*

Matthew Roden, Ph.D.

President & CEO

Brian Goodman, Ph.D.

Co-Founder & CBO

In the News

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

*CEO is not receiving direct compensation for this quote, but is the CEO of a portfolio company that MPM BioImpact invests in and has a pecuniary interest that arises from the relationship. Matthew is also a member of MPM BioImpact’s investment committee and receives compensation from certain MPM BioImpact funds.

“MPM BioImpact is a founding investor and continues to be a key partner as we power advanced therapies through our technology stack and end-to-end manufacturing capabilities.”*

David Hallal

ChaIRman & CEO

Ansbert Gadicke, M.D.

Co-Founder &  Board Member

In the News

Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases

*CEO is not receiving direct compensation for this quote, but is the CEO of a portfolio company that MPM BioImpact invests in and has a pecuniary interest that arises from the relationship.

“MPM BioImpact and Dr. Gordon Freeman, pioneer of the PD-1 pathway and NextPoint's scientific co-founder, have a long history of creating transformative cancer therapies together. Building on this partnership, we assembled a world-class team of drug developers to bring the next generation of cancer immunotherapies to patients.”*

Detlev Biniszkiewicz, Ph.D.

CO-FOUNDER & FOUNDING CEO

Gordon Freeman, Ph.D.

CO-FOUNDER & PROFESSOR, DFCI & HARVARD MEDICAL SCHOOL

XingXing Zang, Ph.D.

CO-FOUNDER & PROFESSOR, ALBERT EINSTEIN COLLEGE OF MEDICINE

*CEO is not receiving direct compensation for this quote, but is the CEO of a portfolio company that MPM BioImpact invests in and has a pecuniary interest that arises from the relationship. Detlev is also a member of MPM BioImpact’s investment committee and receives compensation from certain MPM BioImpact funds.

Meet our Team

MPM BioImpact’s investment team consists of professionals who have dedicated their careers to research and drug development, company creation, corporate strategy, and commercialization. Our Entrepreneur Partners provide deep domain expertise as investor-operators and work with our diverse group of scientists and professionals to develop therapies for diseases with high unmet needs. Collectively, we are a team of deeply experienced company creators who help transform scientific discoveries into breakthrough medicines for the patients that need them most.

Learn about our team of experts